Recent Updates
Recently added Catalysts
CUVL Neutral Sentiment

Appendix 3H — Notification of cessation of securities

Monday, July 27, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CLINUVEL has issued a notification regarding the cessation of certain securities. The announcement is part of their ongoing corporate governance and investor relations activities. Further details about the implications of this cessation were not provided in the article.
Price reaction · baseline $6.95 (2026-07-23 close) · 2 other CUVL headline(s) in the window, move may be shared
day 0 close
+0.9%

Market Sentiment Analysis

Full Press Release Details

• About About CLINUVEL People Corporate Governance Photomedicine Foundation Annual Reports
• Pharmaceuticals Pharmaceutical Development The Science Disease Entities Products
• PhotoCosmetics About PhotoCosmetics Polychromatic Photoprotection DNA Repair Melanogenesis
• Investors Investors Information ASX Announcements SEC Filings Analyst Coverage Media Coverage Company Snapshot Financial Summary Shareholder Information Investor Enquiry
• News
• Contact
• Store
• About CLINUVEL
• People
• Corporate Governance
• Photomedicine Foundation
• Annual Reports
• Pharmaceutical Development
• The Science
• Disease Entities
• Products
• About PhotoCosmetics
• Polychromatic Photoprotection
• DNA Repair
• Melanogenesis
• Investors Information
• ASX Announcements
• SEC Filings
• Analyst Coverage
• Media Coverage
• Company Snapshot
• Financial Summary
• Shareholder Information
• Investor Enquiry
ShareAdd on Google
Tags: CUVL Viatris Investor Conferences Healthcare CLINUVEL securities ASX investors corporate governance
Last updated: Jul 27, 2026

Biotech snapshot

Lead asset
Afamelanotide and NB-UVB LightPhase 3
Vitiligo →